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Introduction
Chronic obstructive pulmonary disease (COPD) is
one of the main causes of morbidity and mortality.
It generates a considerable social burden and has an
unfavourable outlook in terms of prevalence and
mortality in the coming decades (1–5).
To date, several studies have analysed the ﬁnancial,
clinical and pharmacological aspects of COPD. Nev-
ertheless, there is a little information on the most
relevant aspects of the disease for patients, as the
severity of the patient’s condition does not often cor-
relate with the functional classiﬁcation or the
resources used. Therefore, in COPD, the term con-
trol usually has a different meaning for physicians,
patients and the health authorities (6–9).
Although physicians and patients have not always
agreed on this view of the condition, it has meant
that in recent years, integrated management of
COPD has begun to include patient-oriented vari-
ables. However, this approach has been limited by
the lack of reliable validated tools that enable us to
record the real needs of the patients.
In recent years, a solution has been developed in
the form of questionnaires (generic and speciﬁc)
examining the quality of life (QOL) and health sta-
tus, and these have been used in patients suffering
from respiratory conditions, especially asthma and
COPD. However, these are complex, designed to
evaluate populations and not subjects – with the
result that they are of little use in clinical practice –
and can underestimate the impact of the disease on
the patient. In fact, COPD can affect lifestyle consid-
erably, to the extent that patients often end up
reducing their participation in many activities and
restricting their social interaction (10–14).
SUMMARY
Background: Health-related quality of life measures are widely used in patients with
chronic obstructive pulmonary disease (COPD). However, they are extremely limited
when used to evaluate patients outside the clinical trials. The aim of this study was to
analyse the burden of the disease using a simple, validated, self-administered ques-
tionnaire speciﬁcally developed for patients in daily clinical practice. Methods: A
total of 3935 patients (74.5% men; mean age, 67 years) participated in a cross-sec-
tional study. The burden of COPD on patients was measured using the Clinical COPD
Questionnaire (CCQ). COPD was rated at four levels by the forced expiratory volume
in one second (FEV1) according to The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) scale. Results: The disease mainly affects old men (more than 50%
were over 65 years of age) and non-employed men (23% were employed). Of the
patients studied, 22.7% continued smoking, especially men (24.4% of men vs.
18.1% of women). Most patients (54%) were diagnosed with moderate stage II
COPD. Severity of COPD was lower in women: 29.6% of men had severe COPD com-
pared with 13.7% of women. During the last year, 65.1% had at least one acute
exacerbation and 36.6% were admitted to hospital because of COPD exacerbation.
No association was found between the body mass index and COPD stage. The vari-
able that most inﬂuenced the disease burden was dyspnoea, as progression from
grade 0 to grade 4 increased the disease burden by 1.78 points for symptoms, 2.43
for functional state and 1.53 for mental state. The functional classiﬁcation of COPD
also had a signiﬁcant inﬂuence on the disease burden. Conclusions: The present
ﬁndings show that dyspnoea and the degree of airﬂow limitation are the clinical vari-
ables that most affect the burden of COPD from the patient’s point of view.
What’s known
• From a clinical point of view, the impact of
COPD in the patient depends on several
variables.
• Quality of life questionnaires are complex and
difﬁcult to use in clinical practice.
What’s new
• Among several variables related with the clinical
situation of a COPD patient, the present ﬁndings
show that dyspnoea and the degree of airﬂow
limitation are the clinical variables that most
affect the burden of COPD from the patient’s
point of view.
• A speciﬁc instrument called the Clinical COPD
Questionnaire can be introduced in clinical
practice as a simple tool to evaluate the global
impact of the disease in each patient.
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a speciﬁc instrument called the Clinical COPD Ques-
tionnaire (CCQ) has been developed and validated.
It contains 10 items that are used to evaluate the
general status of the COPD patient. The items are
grouped in three domains: symptoms, functional
state and mental state. The CCQ is self-administered
and takes the patient no more than 2 min to com-
plete (15,16).
This study aims to use this questionnaire to evalu-
ate the burden of the disease in standard clinical
practice and analyse its relationship with the clinical
and functional aspects of severity, cultural factors
and socioeconomic factors. This study represents the
ﬁrst use of the CCQ in clinical practice outside the
context of a clinical trial, in our setting, and in Span-
ish.
Materials and methods
Ours was a cross-sectional, epidemiological, observa-
tional clinical study carried out in Spain between
January 2005 and February 2006 in pulmonology
and primary care clinics among patients with a pre-
vious diagnosis of COPD. All patients were stable
during the last month (clinical status and treatment
had to be unaltered during the previous month) and
were referred to outpatient clinics for regular moni-
toring. A total of 665 primary care doctors and 90
specialists contributed to the recruitment. Diagnosis
and severity of the obstruction were established using
the GOLD criteria. No spirometry was carried out
during the study. To be included, patients had to
have a previous diagnosis of spirometry-conﬁrmed
COPD. The values of this spirometry were used as
reference values for establishing severity according to
the GOLD classiﬁcation. To avoid selection bias, the
investigator included the ﬁrst ﬁve patients fulﬁlling
the selection criteria (Table 1). Additional cases were
recruited by some doctors and they were also
included in the study.
A single observation was made in which demo-
graphical data, data related to the study disease and
socioeconomic data were collected. Patients com-
pleted the self-administered CCQ. Information was
taken from the clinical history and the case report
forms (CRF) designed for the study. The main
investigator was in charge of collecting information
from all the collaborating investigators, who were in
turn responsible for including the patient in the
study, obtaining informed consent and obtaining
the necessary data, all in accordance with the study
protocol. The study was approved by the Ethics
Committee of Hospital de la Princesa (Madrid.
Spain).
Predetermination of the sample size
Disease burden was measured using the CCQ both
globally and individually for each of the progressive
stages of COPD (mild, moderate, severe and very
severe). It was necessary to enrol 3800 patients to
obtain a 95% conﬁdence interval (CI) for the median
score obtained from the CCQ. An estimated standard
deviation of 1.7 was assumed, with an accuracy of
0.1 in the least frequent stage of COPD (very severe).
The estimated level of losses was 10%. The ‘10% esti-
mated losses’ refers to those on the CRF. This was
because of the missing information that would have
prevented us from having totally completed ques-
tionnaires.
Measurement of disease burden using a
speciﬁc instrument
The CCQ was originally validated for English-speak-
ing countries and recently validated for Spain (sub-
mitted). It is composed of 10 questions using a
Likert-type scale with scores ranging from 0 to 6
(never–almost always).
The replies are grouped into three domains –
symptoms, functional state and mental state – all of
which refer to the week before the questionnaire was
completed. A global score is provided, and this is
summarised as a measure of the disease burden rang-
ing from 0 to 6. The CCQ is self-administered and
takes the patient no longer than 2 min to complete.
The questionnaire is self-applied and the investiga-
tors were given instructions to interfere as little as
Table 1 Selection criteria
Inclusion criteria
All of the following inclusion criteria must be fulﬁlled:
Patients must be aged at least 40 years with diagnosed
COPD in stages I–IV according to the GOLD guidelines
Patients must have been stable during the previous
month, that is, with no change in their treatment
for COPD
Patients must have given their informed consent to
participate in the study
Exclusion criteria
Patients must not present any of the following criteria:
Terminal illness (life expectancy of < 6 months)
Diagnosed psychiatric condition or any other condition
that modiﬁes perceived health status or that prevents
informed consent from being given
Inability to understand spoken or written Spanish
Modiﬁcation of COPD treatment within the last month
Likely to be admitted to hospital or an institution at
enrolment because of their COPD
COPD, chronic obstructive pulmonary disease; GOLD, The
Global Initiative for Chronic Obstructive Lung Disease.
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was evaluated by the Modiﬁed Medical Research
Council score.
The study was carried out according to the ethical
principles established for research in human beings
in the Declaration of Helsinki and its subsequent
revisions. The protocol was approved by the Ethics
Committee. Patients were included once written
informed consent had been obtained.
Statistical analysis
The primary variable (evaluation of the disease bur-
den for a COPD patient measured by the CCQ) was
analysed globally and individually for each of the
progressive stages of COPD (mild, moderate, severe
and very severe).
For the global score and that of each dimension,
we calculated the mean, standard deviation, median,
range and 95% CI. To identify the risk factors associ-
ated with the burden of COPD, we compared the
mean scores of each dimension.
The t-test was used to evaluate signiﬁcant differ-
ences for comparisons between two groups and a
one-way analysis of variance for comparisons
between more than two groups. We assumed a nor-
mal distribution because the global score and dimen-
sions are a sum of items, and the analysed
population size was large enough (Central Limit The-
orem).
Multivariate models were constructed in which the
burden of COPD was taken as a dependent variable,
and the potential determinants (severity, socioeco-
nomic factors and cultural factors) were included in
the model as independent variables. Each of the vari-
ables was included in the model according to the
results of the bivariate analyses. We deleted those
variables in the model with the highest p-values,
until all remaining variables had a p-value £ 0.20.
The differences were only considered statistically sig-
niﬁcant if p < 0.05.
Results
The study included 3935 patients with COPD of
whom 316 were excluded for not fulﬁlling the eligi-
bility criteria. When we had missing information
because of incomplete questionnaires, the patient was
also excluded. A total of 3619 patients (91.97%)
enrolled by 755 physicians were analysed. Functional
severity in both levels is showed in Table 2.
Table 3 shows the demographical and clinical data.
The disease mainly affected adult men (more than
50% were over 65 years old) who were not active
(23% were working). Of the total number of
patients, 22.7% continued smoking, especially men
(24.4% vs. 18.1%). Most of the patients (54%) were
diagnosed with moderate stage II COPD. Severity of
COPD was lower in women: 29.6% of men had
severe COPD compared with 13.7% of women. Dur-
ing the previous year, 65.1% experienced at least one
acute exacerbation and 36.6% were admitted to hos-
pital because of COPD. No association was found
between body mass index (BMI) and COPD stage.
As for pharmacological therapy, 79% of the
patients analysed were taking inhaled corticosteroids,
more than 60% were taking b2-agonists (short-acting
or long-acting) and more than half (55.4%) were
taking anticholinergic drugs.
Figure 1 shows the average values for the CCQ in
the whole population. The mean burden of the dis-
ease was 2.5. During the 7 days before the study, the
patients analysed rarely felt depressed, sad, or
that they could not breathe while resting because
of their respiratory problems (mean response
approximately 2). They were slightly limited (mean
response approximately 2) in their daily or social
activities during the 7 days before the study. For the
remaining questions, their mean response varied
around 3.
Women had a lower disease burden than men
(2.32 ± 1.15 vs. 2.51 ± 1.22; p £0.0001). The disease
burden of the younger patients was lower than that
of the older patients (over 50 years of age). These
differences were statistically signiﬁcant. The Spear-
man correlation coefﬁcient conﬁrmed the association
between age and disease burden. This association was
positive in the sense that the higher the age, the
greater the burden was. Non-smokers had a lower
burden than ex-smokers: 2.37 ± 1.15 vs. 2.53 ± 1.23;
p = 0.0066. It was observed that the patients who
did not have a severe acute exacerbation or admis-
sion during the 12 months before the analysis
Table 2 Healthcare setting and COPD severity
Stage I Stage II Stage III Stage IV Total
Primary care 649 (20.56%) 1755 (55.59%) 666 (21.09%) 87 (2.75%) 3157 (100%)
Pneumology 67 (16.22%) 173 (41.88%) 124 (30.02%) 49 (11.86%) 413 (100%)
Total 716 (20.05%) 1928 (54.00%) 790 (22.13%) 136 (3.80%) 3570 (100%)
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were statistically signiﬁcant. The Spearman correla-
tion coefﬁcient conﬁrmed the association between
the number of admissions and the disease burden.
To study the factors affecting the disease burden, a
multivariate linear regression analysis was carried
out. This included those variables that had reached
statistical signiﬁcance in the bivariate analysis: sex,
age, smoking, education, activity, years since diagno-
sis of COPD, COPD classiﬁcation, dyspnoea scale,
number of hospitalisations, number of acute exacer-
bations and treatment. The inﬂuence of all the vari-
ables on the disease burden was statistically
signiﬁcant, except for age, which was no longer sta-
tistically signiﬁcant when it was evaluated along with
the other variables. When we constructed the model
with the variables that reached predeﬁned statistical
signiﬁcance (p < 0.2), sex remained on multivariate
analysis (although the difference between the sexes
did not reach statistical signiﬁcance). By contrast,
Table 3 Characteristics of the study population
Total Men Women p-value
No. 3619 2610 850
Percentage 74.5 24.6
Age [mean (SD)] 67.0 (10.8) 67.4 (10.4) 65.9 (11.9) 0.0002
BMI [mean (SD)] 27.9 (4.1) 28.0 (3.9) 27.8 (4.8) 0.2700
Smoking history (%) < 0.0001
Non-smoker 20.5 7.3 63.2
Ex-smoker 56.7 68.3 18.7
Active smoker 22.7 24.4 18.1
Education (%) 0.0002
None 20 18.5 25.2
Primary 55.3 57.2 50.6
Secondary 18.8 18.9 17.8
Higher 5.9 5.4 6.4
Activity (%) < 0.0001
Employed 23 24.4 18.1
Homemaker 11.7 0.5 46.9
Unemployed 2.4 2.9 0.8
Permanently disabled 7 8.5 2.6
Retired 55.9 63.7 31.6
COPD classiﬁcation (GOLD criteria) (%) < 0.0001
Mild COPD. Stage I 20.1 16.9 29.6
Moderate COPD. Stage II 54 53.5 56.7
Severe COPD. Stage III 22.1 25.2 11.8
Very severe COPD. Stage IV 3.8 4.4 1.9
Dyspnoea scale (%) (MMRC) < 0.0001
Grade 0 19.9 17.9 25.9
Grade 1 38.7 38.1 41.2
Grade 2 23.5 25.0 18.3
Grade 3 14 14.7 12.2
Grade 4 3.9 4.3 2.4
Number of acute exacerbations during the past year (%) 0.0050
0 34.9 38.3 34.8
1 25 25.3 25.2
2 18.8 19.1 18.7
‡ 3 21.4 17.3 21.3
Number of hospitalisations during the past year (%) < 0.0001
0 63.4 69.1 63.4
1 22.6 21.9 22.6
2 8.7 5.4 8.7
‡ 3 5.4 3.6 5.3
BMI, body mass index; COPD, chronic obstructive pulmonary disease; MMRC, Modiﬁed Medical Research Council Score; GOLD, The
Global Initiative for Chronic Obstructive Lung Disease.
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it did not reach statistical signiﬁcance (p = 0.62).
The variable that most affected the disease burden
was dyspnoea. When dyspnoea progressed from
grade 0 to grade 4, disease burden increased by 1.98
points. In addition to this variable, functional classi-
ﬁcation of COPD was observed to affect the disease
burden (Table 4).
The responses to the CCQ are grouped into three
domains: symptoms, functional state and mental state.
The variable with the greatest inﬂuence on disease
burden in the three domains analysed individually was
dyspnoea – when it progressed from grade 0 to grade
4, disease burden increased by 1.78 points for symp-
toms, 2.43 for functional state and 1.53 for mental
state. Furthermore, functional classiﬁcation of COPD
also affected the disease burden (Tables 5, 6, 7).
Although there were signiﬁcant differences
between the sexes, especially in the mental state
domain (0.30; 0.14–0.45), these were not clinically
relevant.
Patients treated in primary healthcare had a lower
disease burden than those treated by specialist cen-
tres (2.42 ± 1.17 vs. 2.72 ± 1.40; p < 0.0001). These
differences were maintained for symptoms
(2.62 ± 1.24 vs. 2.95 ± 1.43; p < 0.0001), functional
state (2.16 ± 1.30 vs. 2.53 ± 1.61; p < 0.0001) and
mental state (2.54 ± 1.46 vs. 2.63 ± 1.40;
p < 0.0001).
Discussion
The most important contribution of this study is
that, from the patient’s point of view, dyspnoea and
degree of airﬂow obstruction are the clinical variables
with the most relevance in disease burden. As the
study is cross-sectional, this association does not nec-
essarily imply causality. Other variables associated
with the burden of COPD were sex, age, smoking,
education, activity, years from diagnosis, number of
acute exacerbations and number of hospitalisations.
These ﬁndings are representative of a non-selected
population attended by primary care physicians and
pulmonologists in our setting.
The burden of COPD is considerable in all senses.
In social terms, mortality is very high and will con-
tinue to increase in the coming years. Thus, it is cur-
rently the ﬁfth cause of death in Spain and is
expected to be the third cause of death in the world
by the year 2020 (17,18).
Clinics are attending more and more patients suf-
fering from this illness. In fact, visits to primary care
centres because of COPD are two to four times more
frequent than visits because of chest pain in patients
with ischaemic heart disease (19). As far as health
systems are concerned, the burden of COPD is
increasing, mainly because of the costs generated by
acute exacerbations and hospital treatment. In Spain,
the annual cost of COPD is estimated to be
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Figure 1 Mean score in the chronic obstructive pulmonary disease clinical questionnaire (mean ± SD) On average, during
the past week, how often did you feel: 1. Short of breath at rest? 2. Short of breath doing physical activities? 3.
Concerned about getting a cold or your breathing getting worse? 4. Depressed (down) because of your breathing
problems? In general, during the past week, how much of the time: 5. Did you cough? 6. Did you produce phlegm? On
average, during the past week, how limited were you in these activities because of your breathing problems: 7.
Strenuous physical activities (such as climbing stairs, hurrying, doing sports)? 8. Moderate physical activities (such as
walking, housework, carrying things)? 9. Daily activities at home (such as dressing, washing yourself)? 10. Social activities
(such as talking, being with children, visiting friends⁄relatives)?
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of the total cost (20).
From the patient’s point of view, COPD is
responsible for the disability that restricts many
daily activities. Today, QOL in COPD is an inde-
pendent parameter of prognosis in the medium
term (21). Nevertheless, despite the considerable
burden of this disease, which affects all aspects of
life, it seems that its impact is not taken as seri-
ously as it should be. COPD symptoms are usually
Table 4 Disease burden. Total score
Source of variation
Bivariate analysis
Adjusted
mean*
Multivariate analysis
Mean CI
P ANOVA
or t-test CI
P compared with
control group General P**
Treatment p < 0.0001 < 0.0001
Bronchodilator 2.6 (2.5–2.7) 2.79 (2.69–2.9)
Bronchodilator + inhaled
corticosteroids
2.8 (2.7–2.8) 2.84 (2.76–2.92) 0.4834
Bronchodilator + oral
corticosteroids
3.3 (3.2–3.4) 3.07 (2.97–3.17) < 0.0001
Sex p < 0.0001 0.1667
Men 2.51 (2.46–2.55) 2.87
Women 2.32 (2.24–2.40) 2.93 (2.84–3.03) 0.17
COPD classiﬁcation p < 0.0001 < 0.0001
Mild COPD. Stage I 1.52 (1.45–1.60) 2.57 (2.46–2.68)
Moderate COPD. Stage II 2.32 (2.27–2.36) 2.70 (2.62–2.79) 0.03
Severe COPD. Stage III 3.41 (3.34–3.47) 3.05 (2.95–3.15) < 0.0001
Very severe COPD. Stage IV 4.02 (3.86–4.19) 3.28 (3.11–3.45) < 0.0001
Education p < 0.0001 0.0004
None 2.81 (2.72–2.90) 3.04 (2.94–3.13)
Primary 2.48 (2.42–2.53) 2.92 (2.84–3) 0.02
Secondary 2.28 (2.19–2.37) 2.92 (2.82–3.02) 0.08
Higher 1.91 (1.74–2.07) 2.72 (2.58–2.87) 0.00
Activity p < 0.0001 0.0934
Employed 1.83 (1.75–1.91) 2.81 (2.72–2.9)
Homemaker 2.26 (2.14–2.37) 2.84 (2.72–2.96) 0.98
Unemployed 2.54 (2.29–2.79) 3.02 (2.82–3.23) 0.15
Permanently disabled 3.11 (2.97–3.26) 2.91 (2.78–3.04) 0.45
Retired 2.72 (2.67–2.77) 2.92 (0–0.22) 0.07
Dyspnoea scale (%)
(MMRC)
p < 0.0001 < 0.0001
Grade 0 1.38 (1.31–1.45) 1.95 (1.84–2.07)
Grade 1 2.14 (2.09–2.19) 2.39 (2.3–2.49) < 0.0001
Grade 2 2.91 (2.85–2.97) 2.89 (2.79–2.99) < 0.0001
Grade 3 3.58 (3.50–3.66) 3.34 (3.23–3.45) < 0.0001
Grade 4 4.44 (4.29–4.58) 3.93 (3.76–4.11) < 0.0001
Years since diagnosis p < 0.0001 0.2021
0–10 years 2.24 (2.19–2.29) 2.88 (2.8–2.96)
More than 10 years 2.79 (2.73–2.85) 2.92 (2.84–3.01) 0.20
Hospitalisations p < 0.0001 < 0.0001
None 2.05 (2.01–2.10) 2.80 (2.72–2.88)
One or more 3.16 (3.10–3.22) 3.00 (2.92–3.09) < 0.0001
Acute exacerbations p < 0.0001 < 0.0001
None 1.78 (1.72–1.84) 2.74 (2.65–2.83)
One or more 2.82 (2.77–2.86) 3.06 (2.99–3.14) < 0.0001
*Minimum mean square. LS-mean. Adjusted for the remaining variables. **For categorical variables, this is the p-value that contrasts if
there are differences between all the categories of the variable. For ordinal variables, it is the p-value that contrasts if there is a linear
association between the variable categories and the CCQ score. MMRC, Modiﬁed Medical Research Council score; COPD, chronic
obstructive pulmonary disease.
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appreciated that a well-deﬁned, speciﬁc medical
condition has developed. This ignorance of what
COPD is on the part of the patient leads to a delay
in visiting the doctor and receiving adequate treat-
ment to improve symptoms and health-related
QOL. When COPD is eventually diagnosed, the dis-
ease may already be very advanced with severe
involvement of lung function.
The CCQ has been developed to measure the clini-
cal control of COPD by covering the primary aspects
of the disease (symptoms) as well as the secondary
variables directly related to the process and which
are very relevant from the clinical point of view
(mental aspects). This tool enables us to assess how
COPD is monitored; therefore, it is very useful in
the clinical evaluation of the patient and in the anal-
ysis of the response to different therapeutic measures.
In fact, the CCQ has proven to be very sensitive for
detecting clinical improvements after smoking cessa-
tion (16).
Unlike generic or speciﬁc QOL questionnaires, the
CCQ is designed to evaluate speciﬁc patients, but
not populations, and it does not aim to evaluate the
degree of well-being of the patients, who may fre-
quently be affected by aspects not connected with the
condition itself (16). In practice, COPD has a con-
siderable impact on lifestyle, as it reduces the
Table 5 Disease burden – symptoms (multivariate analysis)
Source of variation
Adjusted
mean*
Mean difference
p-value Difference 95% CI
Treatment < 0.0001
Bronchodilator 2.85
Bronchodilator + inhaled corticosteroids 2.94 0.09 ()0.03–0.21)
Bronchodilator + oral corticosteroids 3.17 0.32 (0.17–0.47)
Smoking history < 0.0001
Non-smoker 2.89
Ex-smoker 2.94 0.04 ()0.08–0.17)
Active smoker 3.13 0.24 (0.1–0.37)
Sex 0.0294
Men 3.05
Women 2.93 )0.12 ()0.22 to )0.01)
COPD classiﬁcation < 0.0001
Mild COPD. Stage I 2.64
Moderate COPD. Stage II 2.83 0.19 (0.05–0.33)
Severe COPD. Stage III 3.18 0.55 (0.37–0.73)
Very severe COPD. Stage IV 3.30 0.66 (0.37–0.94)
Education 0.0727
None 3.07
Primary 3.00 )0.07 ()0.18–0.04)
Secondary 3.03 )0.04 ()0.18–0.1)
Higher 2.84 )0.23 ()0.44 to )0.02)
Dyspnoea scale (MMRC) < 0.0001
Grade 0 2.13
Grade 1 2.52 0.39 (0.24–0.53)
Grade 2 2.98 0.85 (0.68–1.02)
Grade 3 3.41 1.28 (1.08–1.48)
Grade 4 3.91 1.78 (1.48–2.08)
Hospitalisations 0.0033
None 2.92
One or more 3.05 0.13 (0.04–0.22)
Acute exacerbations < 0.0001
None 2.80
One or more 3.17 0.37 (0.28–0.45)
*Minimum mean square. LS-mean. Adjusted for the remaining variables. MMRC, Modiﬁed Medical Research Council score; COPD,
chronic obstructive pulmonary disease.
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and restricts social interaction.
This study reports the ﬁrst use of the CCQ in the
clinical practice outside the context of a clinical trial;
therefore, it enables us to measure the burden of the
disease in our setting from the patient’s perspective
and to discover which variables are clinically relevant
in this burden.
Dyspnoea is the variable with the most impact on
disease burden. This is the main symptom of COPD
patients; it limits activities that require physical exer-
tion and, when it is intense, can lead to disability
(22). In practice, the progression from grade 0
dyspnoea to grade 4 dyspnoea means that the burden
of the disease increases globally by 1.78 points, espe-
cially with regard to symptoms. Each increase in the
score represented an increase in the burden of more
than 0.40, which is the limit considered as clinically
signiﬁcant (16).
The relationship between dyspnoea and the
severity of obstruction is weak. This is because of
the complexity of the factors that intervene in the
onset of dyspnoea, which can be physiological and
psychological (22,23). FEV1 is an excellent parame-
ter for evaluating the degree of functional involve-
ment in COPD patients. It is also used to evaluate
Table 6 Disease burden – functional state (multivariate analysis)
Source of variation
Adjusted
mean*
Mean difference
p-value Difference 95% CI
Treatment 0.0005
Bronchodilator 2.70
Bronchodilator + inhaled corticosteroids 2.71 0.01 ()0.1–0.12)
Bronchodilator + oral corticosteroids 2.90 0.20 (0.05–0.35)
Sex 0.0041
Men 2.71
Women 2.83 0.12 (0.04–0.2)
COPD classiﬁcation < 0.0001
Mild COPD. Stage I 2.38
Moderate COPD. Stage II 2.50 0.12 ()0.02 to )0.02)
Severe COPD. Stage III 2.92 0.54 (0.36–0.71)
Very severe COPD. Stage IV 3.28 0.90
Education < 0.0001
None 2.95
Primary 2.79 )0.16 ()0.27 to )0.05)
Secondary 2.78 )0.16 ()0.3 to )0.03)
Higher 2.56 )0.38 ()0.59 to )0.18)
Dyspnoea scale (MMRC) < 0.0001
Grade 0 1.59
Grade 1 2.20 0.61 (0.47–0.75)
Grade 2 2.77 1.18 (1.01–1.34)
Grade 3 3.26 1.67 (1.48–1.87)
Grade 4 4.03 2.43 (2.14–2.73)
Years since diagnosis 0.1759
0–10 2.74
More than 10 2.80 0.05 ()0.02–0.13)
Age 0.0126
Under 70 2.72
Over 70 2.82 0.10 (0.02–0.17)
Hospitalisations < 0.0001
None 2.63
One or more 2.91 0.27 (0.18–0.36)
Acute exacerbations < 0.0001
None 2.67
One or more 2.87 0.20 (0.11–0.29)
*Minimum mean square. LS-mean. Adjusted for the remaining variables. MMRC, Modiﬁed Medical Research Council score; COPD,
chronic obstructive pulmonary disease.
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mortality of COPD. However, unlike reports on
quality-of-life questionnaires, which may be affected
by factors that have nothing to do with the disease
or the patient, our study showed that FEV1
expressed as a percentage of the theoretical value
plays a more important role in COPD burden than
has been appreciated in recent years. In clinical
practice, changes in disease burden are particularly
relevant when the patient progresses to stages III
and IV.
When exacerbations appear, the normal life of
these patients is even more altered and those with
severe alterations can even fear for their life. Severe
exacerbations affect health over a long period, even
after they have been satisfactorily managed. Visits to
the emergency department because of an acute
exacerbation and subsequent admissions to hospital
Table 7 Disease burden – mental state (multivariate analysis)
Source of variation
Adjusted
mean*
Mean difference
p-value Difference 95% CI
Treatment < 0.0001
Bronchodilator 2.76
Bronchodilator + inhaled corticosteroids 2.88 0.12 ()0.02–0.27)
Bronchodilator + oral corticosteroids 3.18 0.42 (0.23–0.61)
Smoking 0.0007
Non-smoker 3.07
Ex-smoker 2.96 )0.11 ()0.28–0.05)
Active smoker 2.78 )0.29 ()0.47 to 0.11)
Sex 0.0002
Men 2.79
Women 3.09 0.30 (0.14–0.45)
COPD classiﬁcation 0.0007
Mild COPD. Stage I 2.69
Moderate COPD. Stage II 2.82 0.14 ()0.04–0.31)
Severe COPD. Stage III 2.82 0.34 (0.11–0.57)
Very severe COPD. Stage IV 3.22 0.53 (0.17–0.89)
Education 0.0101
None 3.09
Primary 3.01 )0.09 ()0.23–0.05)
Secondary 2.93 )0.17 ()0.35–0.02)
Higher 2.72 )0.37 ()0.64 to 0.1)
Activity 0.0089
Employed 2.78
Homemaker 2.79 0.01 ()0.24–0.27)
Unemployed 3.07 0.30 ()0.09–0.69)
Permanently disabled 3.10 0.32 (0.06–0.59)
Retired 2.95 0.18 (0.01–0.35)
Dyspnoea scale (MMRC) < 0.0001
Grade 0 2.23
Grade 1 2.50 0.26 (0.08–0.45)
Grade 2 2.90 0.66 (0.45–0.88)
Grade 3 3.29 1.06 (0.8–1.32)
Grade 4 3.77 1.53 (1.15–1.91)
Hospitalisations < 0.0001
None 2.81
One or more 3.07 0.26 (0.15–0.38)
Acute exacerbations < 0.0001
None 2.72
One or more 3.16 0.44 (0.32–0.55)
*Minimum mean square. LS-mean. Adjusted for the remaining variables. MMRC, Modiﬁed Medical Research Council score; COPD,
chronic obstructive pulmonary disease.
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patients (24). However, the episodic nature of an
acute exacerbation could mean that, from the
patient’s perspective, its impact is lower than that of
dyspnoea and functional deterioration, which mani-
fest themselves on a daily basis.
Malnutrition has been associated with a reduction
in the different respiratory function parameters and
with a deterioration in dyspnoea and QOL in COPD
patients, and is an element of the BODE index (25–
27). In our study, the percentage of underweight
patients was low, similar to that detected in other
studies carried out in Spain, although it is clearly
lower than that found in other countries (28,29). We
found no association between the BMI and disease
burden.
In a recent study (24), sex was a predictor of drug
consumption in COPD patients, and this could indi-
cate differences in burden. Although there were sig-
niﬁcant differences between the sexes, especially in
the mental state domain, these were not clinically rel-
evant.
The number of non-smoker women in this study
was very high. We cannot exclude that there may
have been an error of interpretation of the question
if she was an ex-smoker. However, In Spain, COPD
in women (deﬁned as cigarette smoke related dis-
ease) is still low but there are many old women
(non-smokers) with chronic airﬂow limitation. We
have no further details but, like in another coun-
tries, other diseases such as wood smoke exposure,
previous pulmonary tuberculosis or long life
asthma, can be the potential causes of chronic
obstructive disease in our country and can explain,
at least in part, the result (30,31). Regarding this
topic, Birring et al. (32) observed that COPD in
non-smokers predominantly affects women and has
at least two pathological subgroups, one of which
may be associated with organ-speciﬁc autoimmune
disease. As the authors pointed out, further investi-
gation of this group may disclose novel mechanisms
of ﬁxed airﬂow obstruction, but so far they are
considered as COPD.
In conclusion, in our setting, dyspnoea and the
degree of airﬂow obstruction are the clinical variables
most associated with disease burden from the
patient’s point of view. Unlike speciﬁc QOL ques-
tionnaires, in clinical practice, CCQ enables us to
evaluate patients quickly and gives the advantage of
informing us about the patient’s perception of the
disease. In fact, COPD has an important effect on
patients’ QOL, to the extent that participation in
many types of activity and social interaction are
reduced. This limits the clinical usefulness of QOL
questionnaires.
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